Fixed-dose combination antihypertensive therapy has received interest since the publication of the JNC-VI report. Relatively few head-to-head comparative studies between fixed-dose combinations and first-line monotherapies for hypertension have been published. The objective of this study was to conduct a meta-analysis of various first-line monotherapies and the fixed-dose combination of amlodipine/benazepril. The results of the meta-analysis were used to compare the efficacy and safety of the first-line monotherapies with amlodipine/benazepril. The meta-analysis included 82 studies that included 110 treatment groups (cohorts). The study compared nine different monotherapies and one combination therapy (amlodipine/benazepril). Of the 82 studies, 22 were placebo-controlled and 60 were active treatment controlled. The mean absolute decrease in supine diastolic blood pressure (BP) ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least (13.3 ؎ 3.0 mm Hg; 9.7 ؎ 2.9 mm Hg, respectively). When studies were weighted by sample size, atenolol, verapamil, lisinopril and amlo-
Introduction
Hypertension remains the most common cardiovascular disease in the United States affecting nearly 60 million adults. 1 It is estimated that 50% of patients started on drug therapy fail their initial treatment attempt. 2 Treatment options in these patients include dosage titration, the use of drug combinations, or to switch patients to other therapy. 3 None of these approaches have been demonstrated to be superior over the others. When faced with a patient who has failed initial therapy, 58% of physicians add a second drug from another therapeutic class, 36% switch therapy to a drug from another therapeutic class, and 6% switch therapy to a drug from the same therapeutic class. [3] [4] [5] [6] One of the monotherapies, the thiazide-based drugs, have been the traditional approach. Only recently has the com-dipine/benazepril showed the greatest BP effect. When studies were weighted by variance, amlodipine/benazepril and atenolol showed the greatest BP effect. The percentage of patients controlled on therapy ranged from 54% to 79%. Lisinopril and amlodipine/benazepril showed the greatest percent controlled. The overall incidence of adverse effects ranged from 12.1% to 41.8% with lisinopril having the lowest and nifedipine having the highest incidence. The overall incidence of adverse effects resulting in drug discontinuance ranged from 1.3% to 10.7%, with amlodipine/benazepril having the lowest and nifedipine having the highest incidence. The results of the metaanalysis indicate that amlodipine/benazepril produces above average reductions in BP with a lower than average incidence of overall side effects and the lowest incidence of adverse effects resulting in drug discontinuance. The fixed-dose combination of amlodipine/ benazepril achieves its goal of effective BP lowering with a minimum of significant side effects.
bination drug angiotensin-converting enzyme inhibitors (ACEI) and calcium channel blockers (CCB) been developed and marketed. 7, 8 There are currently four ACEI/CCB combinations marketed in the United States. Of these, the combination of amlodipine and benazepril (Lotrel ® ) has been available for the greatest length of time. The rationale for the use of the ACEI/CCB combinations is to combine drugs with differing mechanisms of action to produce additive blood pressure (BP) lowering while minimizing side effects which occur with higher doses of the individual components. Fixed-dose combinations should be superior to either of the individual components of the product in terms of BP lowering efficacy and dose-limiting side effects.
While the safety and efficacy of monotherapies, combinations of monotherapies, and fixed-dose combination products for the treatment of mild-tomoderate essential hypertension have been extensively reported in the literature, only a limited number of reports have compared the relative efficacy and safety of first-line monotherapies vs fixed-dose combination treatments.
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The meta-analytic approach is one way to rigorously compare the results of a broad base of published reports by applying selection criteria to ensure consistency of design among the sampled reports, and by extracting common end-points for comparison across studies. In its strictest application, meta-analysis is used as an inferential tool to draw conclusions about a treatment with a much larger sample size than can be feasibly targeted by a single study. The larger sample size affords greater statistical power, which enables the detection of more subtle differences among treatment groups. In its most general application, metaanalysis is used as a descriptive tool to compile and review summary statistics derived from many separate studies.
The objective of this study was to conduct a thorough review of recent literature, extract relevant reports of first-line therapies for patients with mildto-moderate essential hypertension (supine diastolic BP of 95 to 115 mm Hg), and to examine the relative safety and efficacy of amlodipine/benazepril with that of first-line monotherapies by using both descriptive and inferential meta-analysis.
Materials and methods
A search of the medical literature was accomplished by using MEDLINE (National Library of Medicine, Bethesda, MD, USA) with the following search terms: 'hypertension, benazepril, atenolol, lisinopril, captopril, hydrochlorothiazide, nifedipine, diltiazem, verapamil, amlodipine, enalapril, randomised controlled trials, safety and efficacy'. The search was further restricted to articles published in English on human subjects between January 1985 and January 1998. Additional studies were identified from pertinent review articles, a review of Current Contents, Clinical Medicine, Institute for Scientific Information, Inc (Philadelphia, PA, USA), and references of the retrieved articles.
The pool of reports that resulted from this initial search strategy was further restricted by applying the following selection criteria. Studies were included if patients were randomly assigned to treatment groups; both placebo-and active-control designs were permitted; and patients must have had mild-to-moderate essential hypertension defined for the purposes of this paper as a baseline supine diastolic BP of 95 to 115 mm Hg. Studies were excluded for the following reasons: the study included Ͻ20 patients per treatment; the treatment duration was Ͻ4 weeks; the study was restricted to the elderly (age у60 years) or adolescents (age Ͻ20 years); the study included patients with a history of poor control with prior antihypertensive therapy; patients were allowed to continue concomitant antihypertension medication during a placebo or baseline run-in phase; patients had significant concomitant diseases such as end-stage renal disease; BP results were not tabulated (ie, shown in figures only); the study was a duplicate record of one that was published elsewhere or was a preliminary study of a larger multicentre trial that was subsequently published in the literature; or the effect of the monotherapy could not be clearly determined before the addition of a second treatment.
The article titles and abstracts that resulted from the MEDLINE search were initially screened for inclusion. Selected articles were then subjected to subsequent review and were further evaluated by two independent reviewers. Disagreements between the two reviewers were resolved by a third reviewer. For some reports, individual treatment groups were eliminated while other treatment groups within the same report were included. The resulting final set of articles was composed of 82 separate reports with a total of 110 treatment groups (cohorts). Of the 82 reports, 22 reports were placebo-controlled, and 60 were active-treatment-controlled.
The following variables were extracted from each report: (1) change in supine diastolic BP from baseline to end of treatment; (2) percentage of patients whose BP was controlled by treatment, where control was defined as supine diastolic BP р90 mm Hg and/or a decrease in supine diastolic BP of у10 mm Hg; (3) incidence of all adverse effects; and (4) incidence of withdrawal because of adverse effects.
The primary measure of efficacy was defined as the absolute change in supine diastolic BP from baseline. This measure was available from all reports with the mean and standard deviation calculated for each treatment. The mean was also weighted by study sample size and according to an estimate of the study variance to address issues of bias in sample size or variance across studies. [95] [96] [97] A placebo-subtracted risk difference was also calculated for placebo-controlled trials. The risk difference is a value that reflects the difference in absolute BP change with active treatment compared to the absolute BP change with placebo.
The secondary measure of efficacy was defined as the percent of patients who achieved control of their BP with treatment. For placebo-controlled trials, a placebo-subtracted risk difference was calculated. The risk difference is a value that reflects the average treatment effect defined as the difference in the percentage of patients controlled on therapy compared to the percentage of patients controlled on placebo. The magnitude of the treatment effect is an important contributing factor to the evaluation of the overall effectiveness of the treatment, as this measure provides an evaluation of within-study effects.
The safety variables were chosen to provide an overall safety profile for each treatment. The incidence of adverse events used for this meta-analysis were based on the numbers of patients reporting at least one adverse event (ie, patient-based percentages). Studies that reported the incidence of adverse events as a percentage of all adverse events (ie, event-based percentages), as well as studies that did not provide adverse event information, were not included in the study. The incidence of withdrawals due to side effects were included if available from the selected studies.
The safety variables and other continuous measures were compared between drug groups by a oneway analysis of variance and the Student-NewmanKeuls multiple range test. The effect of each treat-ment was statistically evaluated by comparing the effect-size measure of Glass et al. 98 For the purposes of this study, effect size was defined as the mean change in supine diastolic BP divided by the standard deviation (s.d.) of the difference. Because the s.d. of this difference was not reported by some studies, an estimate of the s.d. was calculated. 99 The mean effect size and 95% confidence interval (CI) were calculated for each study and for various subgroups determined by the type of treatment and the study design. The effect sizes of all eligible studies were submitted to a chi-square test for homogeneity. This test was done to evaluate the hypothesis that all cohorts were sampled from a population of cohorts having similar effect sizes. 95 
Results
The mean absolute decrease in supine diastolic BP with treatment is summarised in Table 1 . The mean decrease in supine diastolic BP varied from 9.7 to 13.3 mm Hg (NS) across treatments, with verapamil and atenolol showing the greatest decreases (13.3 ± 3.0 mm Hg; 12.4 ± 2.5 mm Hg, respectively). These relative rankings changed when the averages were weighted by sample size with atenolol, verapamil, lisinopril, and amlodipine/benazepril, showing the greatest reductions. When the averages were weighted by the inverse of the variance estimates, atenolol, and amlodipine/benazepril showed the greatest average reductions in supine diastolic BP.
The percentage of patients who achieved BP control with therapy was available for 95 cohorts and is summarised in Table 2. The average percentage of patients defined as controlled after treatment varied from 53.5% to 79.0%, with lisinopril, and amlodipine/benazepril showing the highest percentage control (79.0% ± 13.0% vs 74.3% ± 18.0%, respectively). The risk difference (increase in percent controlled in treatment vs placebo groups) was calculated for the 24 placebo-controlled cohorts. Placebo cohorts were not available for lisinopril or captopril. The highest risk difference was observed with amlodipine/benazepril at 57.2%. When the average risk differences were weighted by the inverse of the variance estimate, the highest ranking treatment was amlodipine/benazepril (53.3%). The numbers of trials, mean and range of doses, maximum and mean treatment duration for each treatment are shown in Table 3 . The mean treatment duration ranged from 8.0 to 10.2 weeks (NS). Table 3 also summarises the safety profiles for each treatment, including the overall rates of adverse events and withdrawals due to adverse events. The incidence of adverse events ranged from 12.1% to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% ± 7.5% and 14.1% ± 18.6% respectively). A significant difference was observed between lisinopril and nifedipine (12.1% ± 7.5% and 41.8% ± 18.7%, P = 0.030). Rates of drug discontinuation ranged from 1.3% for amlodipine/benazepril to a high of 10.7% for nifedipine. The nifedipine cohorts had a significantly higher incidence of withdrawal then hydrochlorothiazide, amlodipine, atenolol, diltiazem, or enalapril cohorts (P = 0.002). The second and third lowest incidence of withdrawal due to adverse events was observed with verapamil (3.0% ± 0.9%) and HCTZ (3.3% ± 3.0%).
Discussion
The Food and Drug Administration's evaluation of new combination antihypertensive therapies are extremely stringent. Three criteria must be satisfied before approval is granted: (1) the combination product must be shown to be more effective than the sum of the effectiveness of either product alone, (2) the combination product must be shown to be at least equally safe relative to the safety of either product used alone, and (3) the risk/benefit ratio of the combination product must be lower than that of either product alone. Amlodipine/benazepril meets these strict criteria in the treatment of hypertension. The results of this meta-analysis indicate that this combination treatment option demonstrates a favourable risk/benefit profile, with above average reductions in BP and a very low rate of drug discontinuance for side effects. Despite a favourable risk/benefit profile, the combination product of amlodipine and benazepril is not approved as firstline therapy for the treatment of hypertension. With respect to the percentage of patients whose BP was defined as controlled after treatment, the relatively small numbers of placebo-controlled trials limits valid conclusions. The consistency of rankings among therapies with respect to the mean decrease in supine diastolic BP when the averages were unweighted vs weighted with sample size or variance demonstrates that these rankings are not an artifact of small or highly variable samples. With respect to the safety profiles of each of the treatments, amlodipine/benazepril had the lowest rate of withdrawals due to adverse events. Lack of significance change was due to the low number of cohorts available for analysis.
Meta-analysis is primarily a descriptive tool that uses quantitative statistical procedures to systematically pool and compare data from studies that were similarly designed and report on common therapies. In the case of this meta-analysis of 82 reports and 110 cohorts of nine different antihypertensive monotherapies and the amlodipine/benazepril combination, comparisons of relative efficacy and safety demonstrates that the combination is an effective option for the treatment of mild-to-moderate essential hypertension. Statistical methods for controlling against bias due to sample size or measurement variance, showed that at least for measures of efficacy, the cohort samples used for these comparisons were relatively unbiased. Since newer therapies obviously have fewer published reports, the results of this meta-analysis can be viewed as a best-estimate of the current information available on the treatments included for comparison.
Relative to first-line monotherapies, combination therapy with amlodipine/benazepril is associated with below-average rates for adverse events and significantly lower rates of withdrawal because of adverse events. Amlodipine/benazepril, has a favourable risk/benefit profile relative to that of other antihypertensive therapies and should be considered early among other choices for the treatment of mild-to-moderate essential hypertension. 
